** Shares of Infinity Pharmaceuticals Inc fall ~43% to $0.12 premarket
** Co says it has terminated merger agreement with cancer therapy developer MEI Pharma Inc
** Says MEIP shareholders did not approve the merger with Infinity
** INFI says will explore strategic alternatives intended to realize the potential value of its lead drug candidate, eganelisib
** Eganelisib is being tested in a mid-stage study for a type of head and neck cancer -INFI
** INFI is entitled to reimbursement of certain expenses and fees of $1 mln from MEIP and also eligible to receive an additional $4 mln under the terms of the merger agreement - INFI
** Up to last close, INFI shares down ~60% this year
(Reporting by Mariam Sunny in Bengaluru)
((Mariam.ESunny@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。